赵天禄,史雨晨,郑泽,柳景华

• 1:首都医科大学附属北京安贞医院心脏内科北京市心肺血管疾病研究所

摘要(Abstract)：

近年来存活心肌评估指导血运重建备受关注，相关技术蓬勃发展，但临床效果存疑。本文综述存活心肌评估现状并汇总相关领域动态，以期探讨存活心肌评估在血运重建术中的地位和预后价值。

关键词(KeyWords)： 存活心肌;冠心病;血运重建

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（81970291、82170344）;; 国家重点基础研究发展计划（973计划）课题（2015CB554404）

作者(Author): 赵天禄,史雨晨,郑泽,柳景华

参考文献(References)：

• [1] Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update:a report from the American Heart Association[J]. Circulation, 2019, 139(10):e56-e528.
• [2] Almeida AG, Carpenter JP, Cameli M, et al. Multimodality imaging of myocardial viability:an expert consensus document from the European Association of Cardiovascular Imaging(EACVI)[J]. Eur Heart J Cardiovasc Imaging,2021,22(8):e97-e125.
• [3] Cwajg JM, Cwajg E, Nagueh SF, et al. End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation:relation to rest-redistribution T1-201 tomography and dobutamine stress echocardiography[J]. J Am Coll Cardiol,2000,35(5):1152-1161.
• [4] Shah DJ, Kim HW, James O, et al. Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease[J]. JAMA,2013,309(9):909-918.
• [5] Brainin P, Haahr-Pedersen S, Olsen FJ, et al. Early systolic lengthening in patients with ST-segment-elevation myocardial infarction:a novel predictor of cardiovascular events[J]. J Am Heart Assoc,2020,9(3):e013835.
• [6] Jamiel A, Ebid M, Ahmed AM, et al. The role of myocardial viability in contemporary cardiac practice[J]. Heart Fail Rev,2017,22(4):401-413.
• [7] Selvanayagam JB, Kardos A, Francis JM, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization[J].Circulation,2004,110(12):1535-1541.
• [8] Choi KM, Kim RJ, Gubernikoff G, et al. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function[J]. Circulation,2001,104(10):1101-1107.
• [9] Romero J, Xue X, Gonzalez W, et al. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease:a meta-analysis of prospective trials[J].JACC Cardiovasc Imaging,2012,5(5):494-508.
• [10] Holtackers RJ, Van De Heyning CM, Chiribiri A, et al.Dark-blood late gadolinium enhancement cardiovascular magnetic resonance for improved detection of subendocardial scar:a review of current techniques[J]. J Cardiovasc Magn Reson,2021,23(1):96.
• [11] Shaaban M, Tantawy SW, Elkafrawy F, et al. Multiparametric rest and dobutamine stress magnetic resonance in assessment of myocardial viability[J]. J Magn Reson Imaging,2021,54(6):1773-1781.
• [12] Garcia MJ, Kwong RY, Scherrer-Crosbie M, et al. State of the art:imaging for myocardial viability:a scientific statement from the American Heart Association[J]. Circ Cardiovasc Imaging,2020,13(7):e000053.
• [13] Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography(PET)nuclear cardiology procedures[J]. J Nucl Cardiol,2016,23(5):1187-1226.
• [14] Mhlanga J, Haq A, Derenoncourt P, et al. 18F-FDG positron emission tomography in myocardial viability assessment:a practical and time efficient protocol[J]. J Nucl Med, 2022,63(4):602-608.
• [15] Shao X, Chen Y, Chen Y, et al. Feasibility and application of trimetazidine in 18F-FDG PET myocardial metabolic imaging of diabetic mellitus patients with severe coronary artery disease:a prospective, self-controlled study[J]. J Nucl Cardiol,2022,29(5):2497-2507.
• [16] Sperry BW. Opportunities to improve image quality in PET myocardial viability imaging in diabetics[J]. J Nucl Cardiol,2022,29(5):2508-2510.
• [17] Lassen ML, Beyer T, Berger A, et al. Data-driven, projectionbased respiratory motion compensation of PET data for cardiac PET/CT and PET/MR imaging[J]. J Nucl Cardiol, 2020, 27(6):2216-2230.
• [18] Sun XX, Li S, Wang Y, et al. Rescue protocol to improve the image quality of 18F-FDG PET/CT myocardial metabolic imaging[J]. Clin Nucl Med, 2021, 46(5):369-374.
• [19] Ladefoged CN, Hasbak P, Hornnes C, et al. Low-dose PET image noise reduction using deep learning:application to cardiac viability FDG imaging in patients with ischemic heart disease[J].Phys Med Biol, 2021, 66(5):054003.
• [20] Kiko T, Yokokawa T, Misaka T, et al. Myocardial viability with chronic total occlusion assessed by hybrid positron emission tomography/magnetic resonance imaging[J]. J Nucl Cardiol,2021, 28(5):2335-2342.
• [21] Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease:a randomized, controlled trial(PARR-2)[J]. J Am Coll Cardiol, 2007, 50(20):2002-2012.
• [22] D’Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation:a substudy of the PARR-2 trial[J].JACC Cardiovasc Imaging, 2009, 2(9):1060-1068.
• [23] Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction:inducible ischemia versus hibernating myocardium[J]. Circ Cardiovasc Imaging, 2013, 6(3):363-372.
• [24] Cleland JG, Calvert M, Freemantle N, et al. The heart failure revascularisation trial(HEART)[J]. Eur J Heart Fail, 2011,13(2):227-233.
• [25] Panza JA, Ellis AM, Al-Khalidi HR, et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy[J]. N Engl J Med, 2019, 381(8):739-748.
• [26] Orlandini A, Castellana N, Pascual A, et al. Myocardial viability for decision-making concerning revascularization in patients with left ventricular dysfunction and coronary artery disease:a meta-analysis of non-randomized and randomized studies[J]. Int J Cardiol,2015, 182:494-499.
• [27] Ryan M, Morgan H, Chiribiri A, et al. Myocardial viability testing:all STICHed up, or about to be REVIVED[J]? Eur Heart J, 2022, 43(2):118-126.
• [28] Perera D, Clayton T, O’Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction[J].N Engl J Med,2022,387(15):1351-1360.
• [29] Sousa-Uva M, Neumann FJ, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur J Cardiothorac Surg,2019,55(1):4-90.
• [30] Kirtane AJ. REVIVE-ing a weak heart-details matter[J]. N Engl J Med. 2022,387(15):1426-1427.